TIMELY ADMINISTRATION OF INSULIN THERAPY IN TYPE 2 DIABETES MELLITUS


Дәйексөз келтіру

Толық мәтін

Аннотация

The article considers the variants of the start of insulin therapy in patients with type 2 diabetes mellitus (DM2), which failed to reach target glycemic control against the background of uses of oral hypoglycemic drugs and lifestyle modifications. The features of different types of basal insulins are discussed. The advantages of use of long-acting insulin analogue glargine for the initiation of insulin therapy in DM2 patients are described. Simple algorithm for titration of doses, convenient mode of administration (once a day), and reduction of the risk of hypoglycaemia, improvement of glycemic control, improvement of health and quality of life allow to recommended insulin glargine for the start of insulin therapy in these patients.

Әдебиет тізімі

  1. http://www.idf.org.
  2. World Health Organization. Prevention of diabetes mellitus. Report of a WHO Study Group. Geneva: World Health Organization 1994;844.
  3. Davis TM, Stratton IM, Fox CJ, et al. U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care 1997;20(9):1435-41.
  4. http://www.who.int. Информационный бюллетень № 312, август 2011.
  5. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005;54(6):1615-25.
  6. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова. 5-й выпуск // Сахарный диабет. 2011. Прил. № 3. С. 14.
  7. U.K. Prospective Study Group: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2002;25(1):28-32.
  8. Lebovitz H. Insulin secretagogues: old and new. Diabetes Rev1999;7:139-53.
  9. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
  10. U.K. Prospective Study Group: Intensive blood glucose control with sulfonylurea's or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS). Lancet 1998;352:837-35.
  11. Holleman F, Wang EC, Bolly GB. Detemir Is Associated with a Higher Insulin Dose Compared to Insulin Glargine across a Wide BMI-Range. 71-th ADA annual meeting. USA, San Diego, Poster Session, 25 June 2011. Abstract:1046.
  12. Hajos T, Pouwer F, De Grooth R, et al. Positive effects of initiation of insulin glargine on glycemic control and emotional well-being in insulin-native type 2 diabetes patients. An observational study in primary care. 69th Annual Meeting and Scientific Sessions of the American Diabetes Association 2009. http://professional.diabetes.org. Abstract:563.
  13. Forst T, Larbig M, Hohberg C, Forst S, Diessel S, Borchert M, Roth W & A. Pfuetzner Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab 2010;12:437-41.
  14. Blickle J-F, Hancu N, Piletic M, et al. Grimaldi. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8 % A1c levels. The TULIP study. Diabetes Obes Metab 2009;11(4):379-86.
  15. Houlden R, Ross S, Harris S, et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study. Diab Res Clin Pract 2007;78:254-58.
  16. Gaal Z, Papp Z, Bako B. Changes in Glycemic Control over 26 Weeks with Basal-Supported Oral Treatment (BOT): An Observational Study in Hungary 2244-PO. Nyíregyháza, Hungary, Miskolc, Hungary. Diabetes 2011;60:582-643.
  17. Gordon J, Pockett RD, Tetlow AP, et al. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract 2010;64(12):1609-18.
  18. Nazimek-Siewniak B, Moczulski D, Grzeszczak W. Risk of macrovascular and microvascular complications in Type 2 diabetes. Results of longitudinal study design. J Diab Complicat 2002;16:271-76.
  19. Karl DM, Gill J, Zhou R, Riddle MC. Clinical Predictors of Risk of Hypoglycemia during Addition and Titration of Insulin Glargine for Type 2 Diabetes. 47th Annual Meeting of the European Association for the study of diabetes. 2011. Abstract:643.
  20. Leany JL, Vlajnic A, Rimler MS. Lower Weight Gain and Better Outcomes in Patients with Type 2 Diabetes Starting Insulin Treatment When Baseline A1C < 8,0 %. 47th Annual Meeting of the European Association for the study of diabetes. 2011. Abstract:670.
  21. Janka HU, Plewe G, Riddle MC, et al. Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes. Diabetes Care 2005;28:254-59.
  22. Pfohl M, Dippel FW, Kostev K, et al. Different persistence on initial basal supported oral therapy in type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany. Int. J Clin Pharmacol Ther 2010;48:761-66.
  23. Weng J, Li Y, Cheng H, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-60.
  24. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a metaanalysis comparing insulin glargine with human NPH in type 2 diabetes. Diabetes Care 2005;28:950-55.
  25. Houlden R, Ross S, Harris S, et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study. Diab Res Clin Pract 2007;78:254-58.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2012

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>